An experimental gut procedure helped a small group of patients maintain up to 80% of weight loss after stopping tirzepatide. A larger trial involving more than 300 people is underway.
Novo Nordisk sues telehealth companies over compounded weight-loss drugs as employers explore AI-based alternatives to costly GLP-1 medications. About 1 in 8 Americans now take GLP-1 drugs for weight loss or diabetes.
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
Multiple television personalities have openly discussed their use of GLP-1 medications for weight loss, with some experiencing facial changes known as "Ozempic face" characterized by volume loss and more pronounced features.
